Imagion Biosystems Ltd. (AU:IBX) has released an update.
Imagion Biosystems Ltd., specialists in cancer detection imaging technology, presented an update at their Annual General Meeting, focused on the progress and challenges of the past year. Despite optimistic clinical results for their MagSense imaging technology and advances in their prostate and ovarian cancer agents, the company faced financial struggles due to a downturn in the Australian capital markets. Moving forward, Imagion plans to operate as a lean virtual entity, aiming to monetize their assets, including their lead imaging agent for breast cancer, and create shareholder value.
For further insights into AU:IBX stock, check out TipRanks’ Stock Analysis page.
